Australia markets close in 4 hours 14 minutes
  • ALL ORDS

    6,822.40
    +10.20 (+0.15%)
     
  • ASX 200

    6,599.80
    +11.30 (+0.17%)
     
  • AUD/USD

    0.7390
    +0.0012 (+0.16%)
     
  • OIL

    44.11
    -0.44 (-0.99%)
     
  • GOLD

    1,816.50
    -2.40 (-0.13%)
     
  • BTC-AUD

    25,516.79
    +121.81 (+0.48%)
     
  • CMC Crypto 200

    369.99
    -9.87 (-2.60%)
     
  • AUD/EUR

    0.6120
    +0.0012 (+0.19%)
     
  • AUD/NZD

    1.0456
    +0.0021 (+0.20%)
     
  • NZX 50

    12,774.49
    +44.59 (+0.35%)
     
  • NASDAQ

    12,455.33
    +187.03 (+1.52%)
     
  • FTSE

    6,384.73
    +118.54 (+1.89%)
     
  • Dow Jones

    29,823.92
    +185.32 (+0.63%)
     
  • DAX

    13,382.30
    +91.10 (+0.69%)
     
  • Hang Seng

    26,567.68
    +226.18 (+0.86%)
     
  • NIKKEI 225

    26,818.75
    +31.21 (+0.12%)
     

Regeneus Ltd (ASX:RGS) Receives Innovation Grant

Sydney, Australia, Dec 18, 2019 - (ABN Newswire) - Regeneus Ltd (ASX:RGS.AX - News) ("Regeneus" or "the Company"), a clinical-stage regenerative medicine company, has received $50K in funding as part of the Innovation Connections Grant from the Australian Government's Department of Industry, Innovation and Science.

The grant has been awarded to the Company under the Department's Entrepreneurs' Programme for Regeneus' study with Monash University, which explores the mode of action of mesenchymal stem cells (MSCs) in pain management. The funding matches Regeneus' project spending over 12 months.

The Innovation Connections Grant aims to help collaboration between businesses and research organisations to develop and implement new ideas with commercial potential.


About Regeneus Ltd:

Regeneus Ltd (ASX:RGS.AX - News) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address significant unmet medical needs in the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain and dermatology.

Contact:

Investor and Media Contact
WE Communications
T: 02 9237 2805
E: WE-AURegeneus@we-worldwide.com

Source:

Regeneus Ltd

Copyright (C) 2019 ABN Newswire. All rights reserved.